Talk:Zoledronic acid

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Zoledronic acid.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Kidney disease?

The article says:

Zoledronate is rapidly processed via the kidneys; consequently its administration is not recommended for patients with reduced renal function or kidney disease.

I'm sure this is true of almost any drugs, but some casual clicking around in Medline and elsewhere didn't turn up anything like this. For example, this article says

tell your doctor if you are being treated wtih radiation therapy and if you have or have ever had heart failure (condition in which the heart cannot pump enough blood to other parts of the body); anemia (condition in which red blood cells cannot bring enought oxygen to the other parts of the body); any condition that stops your blood from clotting normally; problems with your mouth, teeth, or gums; an infection, especially in your mouth; asthma, especially if it is made worse by aspirin; or kidney or liver disease

I'd think almost any drug might stress the kidneys and I'd think any patient ought to tell their doctor about kidney or liver disease before starting any significant course of drug treatment. The article seems to imply that zoledronate has a special risk, requiring a special caution. I have no reason to doubt this, but I'd like to see a citation. Dpbsmith (talk) 15:55, 1 April 2008 (UTC)[reply]

Renal toxicity is an issue for all bisphosphonates as the non bone-binding drug is rapidly cleared by the kidneys. Thus they all have the standard warning regarding patients with compromised kidney function. Here is a citation for a ZA specific report that shows renal impairment in 23.8% of patients.

Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007 Mar 15;109(6):1090-6. PMID: 17311345 Dr Aaron (talk) 13:30, 2 April 2008 (UTC)[reply]

Use in cancer therapy

There is talk of using this drug (and bisphosphonates in general) in the treatment of breast cancer. See: http://www.nytimes.com/2009/02/12/health/research/12bone.html —Preceding unsigned comment added by 86.219.3.19 (talk) 09:29, 19 December 2009 (UTC)[reply]

This is mentioned in the Research section. Rod57 (talk) 14:03, 4 May 2011 (UTC)[reply]

A TED talk by David Agnus mentions this, and a TED talk by Mina Bissel suggests cancer is related to the extra cellular matrix or 'architecture' around the cell becoming damaged and failing to constrict its activity Timpo (talk) 12:53, 29 January 2014 (UTC)[reply]

thank you but TED talks are not OK sources under WP:MEDRS. Jytdog (talk) 13:50, 29 January 2014 (UTC)[reply]

Need a secondary link

These links can be found in a number of recent articles in the review part, but I did not find for them the separate (secondary) review. If anyone knows of a secondary link, please give.

Intravenous administration of Zoledronic acid leads to the production of ApppI (a non-hydrolysable ATP analogue), which is cytotoxic, and inhibits the mitochondrial adenine nucleotide translocase that leads to direct activation of mitochondrial apoptosis^[1]^[2] Dmitry Dzhagarov (talk) 09:11, 25 March 2016 (UTC)[reply]

^ Hannu Mönkkönen, Seppo Auriola, Petri Lehenkari et al., (2006 January 9). A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol.; 147(4): 437–445. doi:10.1038/sj.bjp.0706628 PMC 1616989
^ Mönkkönen, H., et al. (2006). "Zoledronic acid induced IPP/ApppI accumulation in different cancer cell lines". Bone. 38 (3): 58. doi:10.1016/j.bone.2005.12.062. {{cite journal}}: Vancouver style error: non-Latin character in name 2 (help)

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Zoledronic acid. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

Added archive http://web.archive.org/web/20100423105839/http://www.nps.org.au:80/consumers/publications/medicine_update/issues/zoledronic_acid to http://www.nps.org.au/consumers/publications/medicine_update/issues/Zoledronic_acid

When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at {{Sourcecheck}}).

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 23:34, 20 July 2016 (UTC)[reply]

A history section for dates

We could have a History section for rough dates of pivotal trials, and dates of various FDA, EMA etc approvals. (Two FDA approvals seems to have been in August 2001, and March 2003) - Rod57 (talk) 15:50, 22 November 2017 (UTC)[reply]

[1] Hannu Mönkkönen, Seppo Auriola, Petri Lehenkari et al., (2006 January 9). A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol.; 147(4): 437–445. doi:10.1038/sj.bjp.0706628 PMC 1616989

[2] Mönkkönen, H., et al. (2006). "Zoledronic acid induced IPP/ApppI accumulation in different cancer cell lines". Bone. 38 (3): 58. doi:10.1016/j.bone.2005.12.062. {{cite journal}}: Vancouver style error: non-Latin character in name 2 (help)

[1]

[2]